EUVIMEDEUVIMED entdecken
Crossref

Undetectable pre‐radical cystectomy circulating tumour DNA status predicts improved oncological outcomes

Reuben Ben-David iD, Sarah Lidagoster iD, Jack Geduldig iD, Kaushik P Kolanukuduru iD, Yuval Elkun iD, Neeraja Tillu iD, Asher Mandel iD, Mohammed Almoflihi iD, Basil Kaufmann iD, Kyrollis Attalla iD, Reza Mehrazin iD, Peter Wiklund iD und 1 weitere

BJU International · 2025

DOI: 10.1111/bju.16556 ↗

Kurz gefasst

Fachartikel in der Zeitschrift BJU International, 2025. Verfasst von Reuben Ben-David und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Hauptthemen laut MEDLINE: Cystectomy, Urinary Bladder Neoplasms, Circulating Tumor DNA, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 7 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To assess recurrence‐free survival (RFS) in patients with undetectable tumour‐informed circulating tumour DNA (ctDNA) before radical cystectomy (RC) and evaluate if those who converted from detectable to undetectable ctDNA status after RC have similar RFS outcomes as those with persistently undetectable ctDNA status. Patients and Methods Patients who underwent RC had prospectively and longitudinally collected tumour‐informed ctDNA analyses during 2021–2023. ctDNA status was informed from the pre‐RC specimen. The minimal residual disease (MRD) window was defined as the initial 90 days after RC. RFS was evaluated using the Kaplan–Meier method. Cox regression analysis was performed to find predictors of disease recurrence.

Results

The cohort included 135 patients with 647 ctDNA analyses. The median (interquartile range [IQR]) age was 71 (63–77) years. Over a median (IQR) follow‐up of 11 (7–18) months, 41 patients (30%) had a recurrence. Pre‐RC undetectable ctDNA status was found in 54 patients (40%). The RFS rates at 6, 12, and 21 months were 98%, 93%, and 82%, respectively. Of 77 patients with undetectable ctDNA status at the MRD window available for conversion dynamics analysis, 43 had persistently undetectable ctDNA status (both at pre‐RC and MRD window) and 31 converted from pre‐RC detectable to MRD undetectable status (conversion group). The persistently undetectable group had significantly better RFS than the conversion group (log‐rank, P < 0.001), with 12‐month RFS rates of 97% vs 51%, and 18‐month RFS rates of 88% vs 51%, respectively. On Cox multivariate analysis, only the conversion group status predicted disease recurrence.

Conclusions

Patients with undetectable pre‐RC ctDNA status have a favourable prognosis and may be candidates for treatment de‐escalation. Those with persistently undetectable ctDNA had superior RFS compared to the conversion group. Pre‐RC ctDNA status should be incorporated into trials examining ctDNA use in clinical decision‐making.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CystectomyUrinary Bladder NeoplasmsCirculating Tumor DNANeoplasm Recurrence, LocalHumansMaleFemaleAgedMiddle AgedNeoplasm, ResidualProspective StudiesPrognosisDisease-Free Survival

Stichwörter der Autor:innen

adjuvant drug therapycirculating tumour DNAnon‐muscle‐invasive bladder neoplasmstumour biomarkerstumour‐informed ctDNAurinary bladder neoplasms

Substanzen

Circulating Tumor DNA

Autor:innen und Institutionen

  • Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

ORCID-Profile: Reuben Ben-David, Sarah Lidagoster, Jack Geduldig, Kaushik P Kolanukuduru, Yuval Elkun, Neeraja Tillu, Asher Mandel, Mohammed Almoflihi, Basil Kaufmann, Kyrollis Attalla, Reza Mehrazin, Peter Wiklund, John P Sfakianos

Zitieren

APA

Ben-David, R., Lidagoster, S., Geduldig, J., Kolanukuduru, K. P., Elkun, Y., Tillu, N., Mandel, A., Almoflihi, M., Kaufmann, B., Attalla, K., Mehrazin, R., Wiklund, P., & Sfakianos, J. P. (2025). Undetectable pre‐radical cystectomy circulating tumour DNA status predicts improved oncological outcomes. BJU International. https://doi.org/10.1111/bju.16556

Vancouver

Ben-David R, Lidagoster S, Geduldig J, Kolanukuduru KP, Elkun Y, Tillu N, et al. Undetectable pre‐radical cystectomy circulating tumour DNA status predicts improved oncological outcomes. BJU International. 2025. doi:10.1111/bju.16556

BibTeX
@article{BenDavid2025,
  author = {Ben-David, Reuben and Lidagoster, Sarah and Geduldig, Jack and Kolanukuduru, Kaushik P and Elkun, Yuval and Tillu, Neeraja and Mandel, Asher and Almoflihi, Mohammed and Kaufmann, Basil and Attalla, Kyrollis and Mehrazin, Reza and Wiklund, Peter and Sfakianos, John P},
  title = {Undetectable pre‐radical cystectomy circulating tumour DNA status predicts improved oncological outcomes},
  journal = {BJU International},
  year = {2025},
  doi = {10.1111/bju.16556}
}
Kostenlos starten →